BOSTON, Mass. — Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today presented clinical data for CTD402, its investigational allogeneic anti-CD7 CAR-T cell therapy, in two oral sessions at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. The data underscore CTD402’s potential...
Latest News
Ottawa, Canada – Georges Wistaff calls CHEO his family’s second home. They have made more than 100 trips there over the last decade, mostly because of health issues involving their 10-year-old son, Antony. Antony was born prematurely and underwent emergency surgery soon after. That was the start of a medical...
New Haven, Conn. — The eyes have been called the window to the brain. It turns out they also serve as an immunological barrier that protects the organ from pathogens and even tumors, Yale researchers have found. In a new study, researchers showed that vaccines injected into the eyes of...
WASHINGTON, DC – Vosoritide’s first global phase 2 study showed an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a genetic cause of short stature in children, according to researchers from Children’s National Hospital. “This is the first medicine that has been developed to specifically...
An international team of scientists studying a rare genetic disease discovered that a bundle of proteins with the long-established function of keeping chromosomes together also plays an important role in regulating genes in humans. When gene regulation is disrupted in the multisystem genetic disease Cornelia deLange syndrome (CdLS), children may...
EL PASO, Texas – Could the solution to the decades-long battle against malaria be as simple as soap? In a new study published in PLOS Neglected Tropical Diseases, scientists at The University of Texas at El Paso have made a compelling case for it. The team has found that adding small quantities...
NEW YORK, NY — IN8bio, Inc. (NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced a publication in Frontiers in Immunology that reviews IN8bio’s novel approach for solid tumors, such as glioblastoma (GBM), an aggressive form of brain cancer. Cellular therapies, particularly chimeric antigen...
Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocol INB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no cytokine release syndrome (CRS), or immune effector...
CAMBRIDGE, Mass. — Incendia Therapeutics, a biotechnology company focused on disrupting the tumor microenvironment (TME) to improve cancer outcomes, today announced that it will present two posters at the International Thymic Malignancy Interest Group Annual Meeting to be held in Milan, Italy, October 2-4, 2025. Both posters disclose clinical results...
Nashville, Tennessee – A new study in the peer-reviewed Journal of Child and Adolescent Psychopharmacology estimated the incidence of neuroleptic malignant syndrome (NMS), a potentially fatal adverse effect of antipsychotic treatment, among individuals ages 5-24 years. Click here to read the article now. Wayne Ray, PhD, from the Vanderbilt University School of...